US Auto Industry Urges Trump to Block Chinese EV Market Access 
Samsung Shares Slide as Labor Talks Intensify Ahead of Planned Strike 
Nintendo Shares Tumble as Weak Forecast and Rising Switch 2 Costs Worry Investors 
Sony Forecasts Lower 2027 Profit Despite Strong Music and Sensor Growth 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Why the future of marijuana legalization remains hazy despite high public support 
CoreWeave Q1 2026 Revenue Surges as AI Infrastructure Demand Grows 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Democratic Attorneys General Sue Trump Administration Over CDC Childhood Vaccine Schedule Changes 
Ibiden Stock Surges as AI Chip Demand Boosts Profit Outlook 
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1 
GOP Lawmakers Probe Sam Altman and OpenAI Ahead of Potential IPO 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship 
On Tuesday, Pfizer announced its decision to donate the rights of royalties from sales of the cancer drug Bavencio to the American Association for Cancer Research. This move comes as a response to concerns raised by US antitrust regulators regarding Pfizer's proposed $43 billion acquisition of Seagen.
After receiving all necessary regulatory approvals, the deal is set to close on Thursday, nearly nine months since its initial announcement, as per Reuters.
Reorganization and Leadership Changes
Pfizer plans to establish a separate division dedicated to cancer drugs as part of its efforts to streamline operations. Additionally, the company intends to split its remaining commercial business into two divisions, one focused on the United States and the other on the rest of the world.
Chief Commercial Officer Angela Hwang will step down, allowing Aamir Malik to assume the US unit's commercial chief role. In the international unit, Alexandre de Germay will take on the position of commercial chief.
Sales and Financial Outlook
Bavencio, a vital cancer drug, generated sales amounting to $271 million for Pfizer in 2022. This acquisition of Seagen, with its targeted cancer therapies, comes at a crucial time for Pfizer. Facing the anticipated decline in COVID-related sales and the looming threat of generic competition for its top-selling drugs, Pfizer seeks to bolster its oncology portfolio and maintain its position as a leader in the pharmaceutical industry.
However, the acquisition faced scrutiny from the US Federal Trade Commission (FTC) earlier this year. In July, the FTC requested more information on the deal from both parties involved, seeking to ensure compliance with antitrust laws. Despite this additional hurdle, Pfizer remains committed to moving forward with the acquisition and closing the deal as planned.
Business Times noted that Seagen, based in Washington, is recognized as a pioneer of antibody-drug conjugates. These innovative treatments function like "guided missiles," specifically designed to target and destroy cancer cells while sparing healthy cells. With this cutting-edge technology and expertise, Seagen contributes to advancing more effective and targeted cancer therapies.
Photo: Pfizer Newsroom
